Lugano, March 17, 2022 – BigOmics Analytics, a Swiss biodata analytics startup, announces raising additional funding from Eppendorf, a leading life science company that develops and sells instruments, consumables and …
Remix Therapeutics is a Boston-based biotechnology company developing novel small molecule therapies for reprogramming RNA processing and treating disease in entirely new ways. As protein targeting therapies reach the limits …
Bellinzona, Switzerland, December 10, 2021 – BigOmics Analytics SA (“BigOmics”), a Swiss biodata analytics startup, announced today that it raised a total of $1.85 million in financing. This funding will …
We are seeking a highly motivated R/Shiny Bioinformatics Software Developer to join our expanding team. You will be joining a highly collaborative team of developers, bioinformaticians and biologists who work …
BigOmics Analytics is a data analytics SaaS startup for big data in the area of next-generation genomics that wants to change the way bioinformatics is done. BigOmics’ mission is to …
Part of the panic over the Coronavirus is due to not having vaccinated, for the founder of a start-up dedicated to the analysis of big data in the biomedical field …
With the advent of high-throughput ‘omics’ technologies, life scientists are starting to grapple with massive data sets. As Big Omics data continues to grow, biologists start encountering challenges with handling, …
The current Coronavirus epidemic (COVID-19) has been causing widespread panic and has been a major health concern in the past months. Efforts from both governments, pharmaceutical companies and the scientific …
BigOmics Analytics, purveyor of self-service analytics platforms for Big Omics data, has been selected for the EU InvestHorizon Accelerator, a program that supports the best EU startups for 6 months. The prominent …
BigOmics Analytics, purveyor of self-service analytics platforms for Big Omics data, has been selected and joined the Alchemist program, one of Silicon Valley’s most prominent business accelerators. “We are impressed …
